Cardoz AB based in Stockholm has received a capital injection of SEK 100 million. The investment has been made by the Dutch venture capital company, Forbion Capital Partners and the Spanish venture capital company, Ysios Capital Partners together with the existing owner the Swedish venture capital company, HealthCap, which also helped to start the company.
Cardoz develops anti-inflammatory pharmaceuticals to combat heart and vascular disorders. The capital contribution is primarily intended for the execution of a clinical phase II trial of a new drug to combat abdominal aorta aneurism (AAA). At present there are no drugs which combat AAA.
Vinge’s team consisted of responsible partner Johan Winnerblad and Johan Larsson who acted as project manager.
